Related Experiment Video
Updated: Jun 21, 2026

Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models
Published on: August 16, 2010
Statistical and trial design considerations in central nervous system prophylaxis studies
Jennifer A Smith1, Michael Glantz
1Geron Corp, Menlo Park, CA 94025, USA. jsmith@geron.com
Abstract:
The prognosis is very poor for patients with cancer who develop central nervous system (CNS) involvement. Prophylactic therapy may be a viable strategy for patients at high risk of CNS metastases. This article explores the rationale, feasibility, and ethics of prophylactic therapy. We discuss various study design considerations for CNS prophylaxis trials, with particular focus on statistical issues, and provide guidance to clinicians trying to decide how to investigate prophylactic therapy The pool of patients eligible for inclusion in clinical trials is limited. To answer pressing clinical questions, innovative trial designs are needed, along with operational strategies that include risk factor enrichment, target-based end point selection and validation, flexible study accrual and monitoring, and techniques that permit early termination when initial treatment outcomes are poor. Two proposed trials for patients with glioblastoma multiforme and non-Hodgkin lymphoma are presented to highlight design considerations.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Clinical Trials: Overview
Dosage Regimens: Designs and Approaches
Bioavailability Study Design: Healthy Subjects Versus Patients
